行情

LIFE

LIFE

aTyr Pharma
NASDAQ

实时行情|Nasdaq Last Sale

3.750
+0.050
+1.35%
已收盘, 16:00 11/12 EST
开盘
3.820
昨收
3.700
最高
3.830
最低
3.696
成交量
3,935
成交额
--
52周最高
10.08
52周最低
2.760
市值
1,458.82万
市盈率(TTM)
-0.0253
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LIFE 新闻

  • aTyr Pharma to Announce Third Quarter Results on November 14th
  • GlobeNewswire.5天前
  • Benzinga's Top Upgrades, Downgrades For November 5, 2019
  • Benzinga.11/05 15:00
  • H.C. Wainwright Initiates Coverage On aTyr Pharma with Buy Rating, Announces $8 Price Target
  • Benzinga.11/05 13:08
  • 图集|老照片首度公开 回顾亚布力和中国企业家的20年
  • 新浪财经-自媒体综合.11/01 01:03

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

LIFE 简况

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
展开

Webull提供aTyr Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。